Viz.ai to Participate in Morgan Stanley 22nd Annual Healthcare Conference
Viz.ai to Participate in Morgan Stanley 22nd Annual Healthcare Conference
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced Chris Mansi, M.D., CEO and Co-founder, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference on Sept. 4, 2024 at 1:05 p.m. ET in New York, NY.
Dr. Mansi will share how Viz.ai is transforming last mile delivery of AI-powered workflows in healthcare with a broadly deployed AI safety net to ensure no patient is missed, helping providers and life sciences to bridge care gaps and increase patient access to life-saving treatments. With the growing need to reinvent the pharmaceutical commercial model as the Inflation Reduction Act puts pressure on drug prices, Viz.ai’s AI-Powered Care Accelerator is uniquely positioned to guide more patients to the right diagnosis, specialist, and treatment faster.
About Viz.ai
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care across 1,600+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz.ai One™ is an intelligent care coordination solution that identifies more patients with a suspected disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, Viz.ai One delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
Brendi Bluitt
brendi.bluitt@finnpartners.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826984975/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk